Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
santarus.com

See what CB Insights has to offer

Founded Year

1996

Stage

Acq - P2P | Acquired

Total Raised

$42.71M

About Santarus

Santarus is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention and treatment of gastrointestinal diseases and disorders. The company's primary business strategy is to develop and market proprietary products with new formulations, enhanced delivery systems or expanded indications that are based on currently marketed products or compounds that have clinically demonstrated safety and efficacy.

Santarus Headquarter Location

3721 Valley Centre Drive Suite 400

San Diego, California, 92130,

United States

858-314-5700

Latest Santarus News

Bausch Health to fork over $300 million in diabetes antitrust lawsuit

Sep 11, 2021

Pharmaceutical Processing World September 10, 2021 Bausch Health (NYSE/TSX:BHC), formerly known as Valeant Pharmaceuticals, has agreed to pay $300 million to settle allegations that the company paid rivals to keep a generic version of Glumetza off the market. In 2015, the Laval, Canada–based company increased the drug’s price by almost eight-fold. The plaintiff in the class-action suit filed in 2019 has asked U.S. District Judge William Alsup in San Francisco to approve the settlement. The settlement would be significant for pharmaceutical industry standards, although a handful of settlements have been larger. Most notably, fen-phen agreed to pay $3.75 billion in a settlement tied to the diet drug fen-phen in 1999. The 2019 lawsuit was titled, “Re: Glumetza Antitrust Litigation, U.S. District Court, Northern District of California, No. 19-cv-05822.” Glumetza is an extended-release version of metformin hydrochloride, a popular type 2 diabetes treatment. FDA approved Glumetza in 2005, which was initially marketed by Depomed (now Assertio) in conjunction with Santarus. Bausch Health eventually acquired Santarus. Lupin Pharmaceuticals intended to launch a generic version of the drug in 2012, but the prior owners of the drug rights, Assertio and Santarus, allegedly paid to delay the generic until 2016. Bausch Health’s stock was mostly unphased in trading today. BHC shares ticked down 0.59% to $28.45, while the S&P 500 index dipped 0.77%. Bausch Health did not immediately respond to a request for comment. Tell Us What You Think!

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Santarus Patents

Santarus has filed 22 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • G protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/31/2018

2/11/2020

Autoimmune diseases, Dosage forms, Glucocorticoids, Excipients, Drug delivery devices

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/31/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/11/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Autoimmune diseases, Dosage forms, Glucocorticoids, Excipients, Drug delivery devices

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.